Tarsus Pharmaceuticals was upgraded to a Zacks Rank #2 (Buy), signaling improving optimism around its earnings outlook. The note suggests the stock could outperform in the near term, though no specific financial figures or targets were provided.
Tarsus Pharmaceuticals was upgraded to a Zacks Rank #2 (Buy), signaling improving optimism around its earnings outlook. The note suggests the stock could outperform in the near term, though no specific financial figures or targets were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
